

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

**Calcium Chloride Injection BP**

100 mg / mL  
(represents 27 mg [0.7 mmol or 1.4 mEq] Ca<sup>++</sup> / mL)  
(represents 48 mg [1.4 mmol or 1.4 mEq] Cl<sup>-</sup> / mL)

10% Hypertonic solution for intravenous injection

Calcium Replenisher

SteriMax Inc.  
2770 Portland Drive  
Oakville, Ontario  
L6H 6R4

Date of Initial Authorization:  
JAN 28, 2020

Date of Revision:  
SEP 18, 2024

Control Number: 285520

**RECENT MAJOR LABEL CHANGES**

<a href="#">2 CONTRAINDICATIONS</a>	09/2024
-------------------------------------	---------

**TABLE OF CONTENTS**

Sections or subsections that are not applicable at the time of authorization are not listed.

<b>PART I: HEALTH PROFESSIONAL INFORMATION</b> .....	<b>3</b>
<b>1 INDICATIONS</b> .....	<b>4</b>
<b>2 CONTRAINDICATIONS</b> .....	<b>4</b>
<b>4 DOSAGE AND ADMINISTRATION</b> .....	<b>4</b>
4.1 Dosing Considerations .....	4
4.2 Recommended Dose and Dosage Adjustment .....	4
4.4 Administration .....	5
4.5 Missed Dose.....	5
<b>5 OVERDOSAGE</b> .....	<b>5</b>
<b>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</b> .....	<b>5</b>
<b>7 WARNINGS AND PRECAUTIONS</b> .....	<b>6</b>
7.1 Special Populations .....	7
7.1.1 Pregnant Women.....	7
7.1.2 Breastfeeding.....	7
7.1.3 Pediatrics .....	7
7.1.4 Geriatrics .....	7
<b>8 ADVERSE REACTIONS</b> .....	<b>7</b>
8.2 Clinical Trial Adverse Reactions.....	8
8.2.1 Clinical Trial Adverse Reactions – Pediatrics .....	8
8.3 Less Common Clinical Trial Adverse Reactions.....	8
8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics .....	8
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data .....	8
8.5 Post-Market Adverse Reactions .....	8
<b>9 DRUG INTERACTIONS</b> .....	<b>8</b>

9.4	Drug-Drug Interactions .....	8
9.5	Drug-Food Interactions.....	9
9.6	Drug-Herb Interactions .....	9
9.7	Drug-Laboratory Test Interactions.....	9
<b>10</b>	<b>CLINICAL PHARMACOLOGY .....</b>	<b>10</b>
10.1	Mechanism of Action.....	10
10.2	Pharmacodynamics .....	10
10.3	Pharmacokinetics .....	10
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL .....</b>	<b>10</b>
<b>12</b>	<b>SPECIAL HANDLING INSTRUCTIONS .....</b>	<b>10</b>
	<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>11</b>
<b>13.</b>	<b>PHARMACEUTICAL INFORMATION.....</b>	<b>11</b>
<b>14</b>	<b>CLINICAL TRIALS .....</b>	<b>11</b>
14.1	Trial Design and Study Demographics .....	11
14.2	Study Results .....	11
14.3	Comparative Bioavailability Studies .....	11
14.4	Immunogenicity .....	12
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>12</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>12</b>
<b>17</b>	<b>SUPPORTING PRODUCT MONOGRAPHS.....</b>	<b>12</b>
	<b>PATIENT MEDICATION INFORMATION.....</b>	<b>13</b>

## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

Calcium Chloride Injection BP is indicated:

- For the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels,
- In the treatment of magnesium intoxication due to overdosage of magnesium sulfate
- To combat the deleterious effects of hyperkalemia as measured by electrocardiography (ECG), pending correction of the increased potassium level in the extracellular fluid.
- In cardiac resuscitation when weak or inadequate contractions return following defibrillation or when epinephrine injection has failed to strengthen myocardial contractions.

### 2 CONTRAINDICATIONS

Calcium Chloride Injection BP is contraindicated:

- For cardiac resuscitation in the presence of ventricular fibrillation.
- In patients with the risk of existing digitalis toxicity.
- In the treatment of asystole and electromechanical dissociation.
- When mixed or administered simultaneously with ceftriaxone intravenous solutions, even via different infusion lines or at different infusion sites, as it can lead to precipitation of ceftriaxone-calcium (see [7 WARNINGS AND PRECAUTIONS](#)).
- For injection into tissues, since it is irritating to veins and severe necrosis and sloughing may occur. In patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).

### 4 DOSAGE AND ADMINISTRATION

#### 4.1 Dosing Considerations

**Caution: This solution must not be injected intramuscularly or subcutaneously.**

#### 4.2 Recommended Dose and Dosage Adjustment

- The usual adult dosage in hypocalcemic disorders ranges from 200 mg to 1000 mg at intervals of 1 to 3 days, depending on the response of the patient and/or results of serum calcium determinations. Repeated injections may be required because of rapid excretion of calcium.
- In magnesium intoxication, an initial adult dose of 500 mg (5 mL) should be administered promptly and the patient observed for signs of recovery before further doses are given.
- In hyperkalemic ECG disturbances of cardiac function, the dosage of calcium chloride injection should be titrated by constant monitoring of ECG changes during administration.

- In cardiac resuscitation, the usual adult dosage ranges from 500 mg to 1 g (5 to 10 mL) intravenously, or from 200 to 800 mg (2 to 8 mL) when injected into the ventricular cavity.

#### 4.4 Administration

Calcium Chloride Injection BP is administered only by **slow** intravenous injection (not to exceed 1 mL/min) and/or in cardiac resuscitation, by injection into the ventricular cavity. It must not be injected into the myocardium.

The usual precautions for intravenous therapy should be observed. If time permits, the solution should be warmed to body temperature. The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time.

To prevent needle-stick injuries, needles should not be recapped, purposely bent or broken by hand. Place all needles in a sharps disposal container immediately after they have been used.

#### 4.5 Missed Dose

This information is not applicable for this drug product.

### 5 OVERDOSAGE

Too rapid injection may produce lowering of blood pressure and cardiac syncope. Persistent hypercalcemia from calcium overdose is unlikely because of rapid excretion. In the event of untoward effects from excessive calcium administration, the drug should be discontinued promptly, the patient re-evaluated and appropriate countermeasures instituted, if necessary. Symptoms of overdose include: anorexia, nausea, vomiting, constipation, abdominal pain, muscle weakness, mental disturbances, polydipsia, polyuria, bone pain, nephrocalcinosis, renal calculi and, in severe cases, cardiac arrhythmias and coma (see [7 WARNING AND PRECAUTIONS](#) and [8 ADVERSE REACTIONS](#)).

For management of a suspected drug overdose, contact your regional poison control centre.

### 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

**Table 1 – Dosage Forms, Strengths, Composition and Packaging**

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Intravenous or intraventricular cavity injection	10 mL Calcium Chloride solution in a pre-filled, single use syringe ( <a href="#">see Table 2 Dosage Forms</a> ) / 100 mg / mL / Calcium Chloride Dihydrate	Hydrochloric Acid and / or Sodium Hydroxide for pH adjustment, Water for Injection

Calcium Chloride Injection BP is supplied in single-use containers as follows:

**Table 2 – Dosage Forms & Packaging**

Container	Volume	Needle
HYPAK SCF™ Syringe	10 mL	Luer lock

The HYPAK SCF™ Syringe includes a glass syringe barrel with luer tip and PRTC (plastic rigid tip cap) with twist-off mechanism for closure security, as well as a plastic HYPAK™ plunger rod and HYPAK SCF™ plunger stopper. Medication and fluid path are sterile and nonpyrogenic if tip cap is undisturbed and package intact.

## 7 WARNINGS AND PRECAUTIONS

### General

#### **Risk of Ceftriaxone-Calcium Precipitation**

Ceftriaxone must not be mixed or administered simultaneously with any calcium-containing IV solutions, even via different infusion lines or at different infusion sites as it can lead to precipitation of ceftriaxone-calcium (see [2 CONTRAINDICATIONS](#)).

Calcium chloride and ceftriaxone intravenous solutions may be administered sequentially one after another if infusion lines at different sites are used, or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt solution to avoid precipitation.

#### **Aluminum Toxicity**

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired.

Research indicates that patients with impaired kidney function, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicities. Tissue loading may occur at even lower rates of administration.

#### **Risk of Cardiac Toxicity**

Because of its additive effect, calcium should be administered very cautiously to a patient who is digitalized or who is taking effective doses of digitalis or digitalis-like preparations (see [9 DRUG INTERACTIONS](#)).

It is particularly important to prevent a high concentration of calcium from reaching the heart because of the danger of cardiac syncope. Too rapid an injection exceeding 1 mL/min may lead to hypotension and cardiac syncope (see [4 DOSAGE AND ADMINISTRATION](#)). If injected into the ventricular cavity in cardiac resuscitation, it must not be injected into the myocardial tissue.

### **Injection Site Reactions**

Calcium Chloride Injection BP is irritating to veins and must not be injected into tissues, since severe necrosis and sloughing may occur (see [2 CONTRAINDICATIONS](#)).

Injections should be made slowly through a small needle into a large vein to minimize venous irritation and avoid undesirable reactions. Great care should be taken to avoid extravasation or accidental injection into perivascular tissues. Should perivascular infiltration occur, intravenous administration at that site should be discontinued at once. Local infiltration of the affected area with 1% procaine hydrochloride, to which hyaluronidase may be added, will often reduce venospasm and dilute the calcium remaining in the tissues locally. Local application of heat may also be helpful.

## **7.1 Special Populations**

### **7.1.1 Pregnant Women**

Calcium crosses the placenta. There are no adequate and well-controlled studies in pregnant women. Therefore, it is not known whether developmental toxicity may occur with the use of calcium chloride. There are no available animal data that evaluate the drug-associated risk. Calcium chloride should be given to a pregnant woman only if clearly needed.

### **7.1.2 Breastfeeding**

It is not known whether calcium chloride injection would have an impact on the calcium content of the human milk in lactating women. Calcium chloride should be administered to lactating women only if clearly indicated. Studies assessing the effects of calcium chloride in breastfed children have not been performed. Studies to assess the effect of calcium chloride on milk production or excretion have not been performed. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for calcium chloride, and any potential adverse effects on the breastfed child from calcium chloride or from the underlying maternal condition.

### **7.1.3 Pediatrics**

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

### **7.1.4 Geriatrics**

Patients over 65 years of age: An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

## **8 ADVERSE REACTIONS**

## **8.2 Clinical Trial Adverse Reactions**

This information is not available for this drug product.

### **8.2.1 Clinical Trial Adverse Reactions – Pediatrics**

This information is not available for this drug product.

## **8.3 Less Common Clinical Trial Adverse Reactions**

This information is not available for this drug product.

### **8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics**

This information is not available for this drug product.

## **8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data**

This information is not available for this drug product.

## **8.5 Post-Market Adverse Reactions**

Nervous system disorders: Paraesthesia (upon rapid injection), calcium taste

General disorders and administration site conditions: Sense of oppression, sense of “heat wave”, local burning sensation, injection site extravasation, injection site reactions

Vascular disorders: Peripheral vasodilatation

Investigations: Blood pressure decreased

## **9 DRUG INTERACTIONS**

### **9.4 Drug-Drug Interactions**

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).



**Table 3 - Established or Potential Drug-Drug Interactions**

Proper/Common name	Source of Evidence	Effect	Clinical comment
Calcium Channel Blockers	C	Administration of calcium may reduce the response to calcium channel blockers.	Calcium-containing products, like Calcium Chloride Injection, may decrease the effectiveness of calcium channel blocker.
Ceftriaxone	C	Ceftriaxone must not be mixed or administered simultaneously with any calcium-containing IV solutions, even via different infusion lines or at different infusion sites as it can lead to precipitation of ceftriaxone-calcium (see <a href="#">2</a> <b><u>CONTRAINDICATIONS</u></b> ).	Calcium chloride and ceftriaxone intravenous solutions may be administered sequentially one after another if infusion lines at different sites are used, or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt solution to avoid precipitation.
Digitalis or digitalis-like preparations	C		Because of its additive effect, calcium should be administered very cautiously to a patient who is digitalized or who is taking effective doses of digitalis or digitalis-like preparations see <a href="#">7</a> <b><u>WARNINGS AND PRECAUTIONS</u></b> ).

Legend: C = Case Study

### 9.5 Drug-Food Interactions

Interactions with food have not been established.

### 9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

### 9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

## 10 CLINICAL PHARMACOLOGY

### 10.1 Mechanism of Action

Calcium chloride in water dissociates to provide calcium ( $\text{Ca}^{++}$ ) and chloride ( $\text{Cl}^-$ ) ions. They are normal constituents of the body fluids and are dependent on various physiologic mechanisms for maintenance of balance between intake and output.

### 10.2 Pharmacodynamics

The normal serum calcium concentrations range from 8.8 to 10.4 mg/dL (2.2 to 2.6 mM).

### 10.3 Pharmacokinetics

#### Distribution

Body calcium exists in two major compartments in which the skeleton accounts for 99% of the total body calcium, and only 1% of the total body calcium is in the body fluids. The calcium in the body fluids can exist in three forms: ionized (~50%), protein-bound (~40%) and complexed with other anions (~10%). The main calcium-binding proteins include albumin and globulin in serum.

#### Metabolism

Calcium does not undergo any direct metabolism.

#### Elimination

Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.

#### Specific Populations and Conditions

The effect of age, gender, race, renal or hepatic impairments on the pharmacokinetics of calcium have not been evaluated in clinical studies.

## 11 STORAGE, STABILITY AND DISPOSAL

Store between 15°C and 30°C. Protect from freezing. Avoid excessive heat.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use unless the solution is clear and the container or seal is intact. Discard if the solution contains a precipitate.

Single-use; discard unused portion.

## 12 SPECIAL HANDLING INSTRUCTIONS

Liquid in glass vial. Handle with care. Inspect vial for damage prior to assembly.

## PART II: SCIENTIFIC INFORMATION

### 13. PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: Calcium chloride

Chemical name: Calcium; dichloride; dihydrate

Molecular formula and molecular mass:  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  (dihydrate) 147.01 g/mol

Structural formula:



Physicochemical properties:

Calcium Chloride Injection BP is a sterile, nonpyrogenic, hypertonic solution containing 100 mg / mL (0.7 mmol / mL or 1.4 mEq / mL) of calcium chloride, dihydrate (0.7 mmol / mL or 1.4 mEq / mL of  $\text{Ca}^{++}$  and 1.4 mmol / mL or 1.4 mEq / mL of  $\text{Cl}^-$ ) in Water for Injection Ph. Eur. It is provided in a 10 mL prefilled syringe to facilitate intravenous injection. The solution is administered only by intravenous or intraventricular cavity injection as a calcium replenisher.

The solution contains no bacteriostat, antimicrobial agent nor added buffer (except for pH adjustment) and is intended only for use as a single-use injection. When smaller doses are required, the unused portion should be discarded. The pH of calcium chloride injection is 5.5 to 7.5. The solution may contain hydrochloric acid and / or calcium hydroxide for pH adjustment. The osmolar concentration is 2.04 mOsm / mL (calc.).

Calcium Chloride dihydrate Ph. Eur. is chemically designated  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  (dihydrate) white, odourless fragments or granules freely soluble in water.

### 14 CLINICAL TRIALS

#### 14.1 Trial Design and Study Demographics

This information is not available for this drug product.

#### 14.2 Study Results

This information is not available for this drug product.

#### 14.3 Comparative Bioavailability Studies

This information is not available for this drug product.

#### **14.4 Immunogenicity**

This information is not available for this drug product.

#### **15 MICROBIOLOGY**

No microbiological information is required for this drug product.

#### **16 NON-CLINICAL TOXICOLOGY**

This information is not available for this drug product.

#### **17 SUPPORTING PRODUCT MONOGRAPHS**

- 1- Calcium Chloride Injection USP, solution, 100 mg / mL, submission control 262054, Product Monograph, Pfizer Canada ULC. (AUG 25, 2022)

## PATIENT MEDICATION INFORMATION

### READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

#### Calcium Chloride Injection BP

Read this carefully before you start taking **Calcium Chloride Injection BP** and each time you get an injection. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Calcium Chloride Injection BP**.

#### What is Calcium Chloride Injection BP used for?

Calcium Chloride Injection BP is used in **adults**:

- to treat low calcium levels in the blood
- to treat magnesium intoxication due to overdosage of magnesium sulfate
- to treat high potassium levels in blood
- as part of the resuscitation procedure following a cardiac arrest (when defibrillation leaves the heart weak, or when epinephrine does not work)

#### How does Calcium Chloride Injection BP work?

Calcium Chloride Injection BP works by supplying more calcium and chloride minerals to your body when your body does not have the right balance.

#### What are the ingredients in Calcium Chloride Injection BP?

Medicinal ingredients: calcium chloride dihydrate

Non-medicinal ingredients: Hydrochloric Acid and/or Sodium Hydroxide for pH adjustment, Water for Injection

#### Calcium Chloride Injection BP comes in the following dosage forms:

Solution in a single-use pre-filled syringe: 100 mg/mL

#### Do not use Calcium Chloride Injection BP if:

- you are allergic to calcium chloride, or to any other ingredient in the formulation
- you have ventricular fibrillation (a dangerous irregular heartbeat)
- you are at risk of existing digitalis toxicity
- you are being treated for asystole and electromechanical dissociation
- administered for injection into tissues, since it is irritating to veins and severe death of body tissue and shedding may occur
- you are currently receiving ceftriaxone (an antibiotic) injections

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Calcium Chloride Injection BP. Talk about any health conditions or**

**problems you may have, including if you:**

- have any kidney problems
- are taking or have recently taken digitalis, or digitalis-like preparations for heart problems
- are taking any calcium channel blockers
- are pregnant, or think you are pregnant
- are breastfeeding

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with Calcium Chloride Injection BP:**

- ceftriaxone (an antibiotic)
- digitalis or digitalis-like preparations for heart problems
- medicines called “calcium channel blockers”

**How to take Calcium Chloride Injection BP:**

- Calcium Chloride Injection BP is given to you by a healthcare professional in a healthcare setting.
- Calcium Chloride Injection BP is given by slow injection into a vein.
- If you feel any discomfort during the injection, tell your healthcare professional.

**Usual dose:**

The dose of Calcium Chloride Injection BP is decided by a healthcare professional.

**Overdose:**

Since the injection is given to you by a healthcare professional, it is unlikely that you will be given too much. However, symptoms of an overdosage may include:

- anorexia
- nausea or vomiting
- constipation or stomach pain
- muscle weakness
- mental disturbances
- feeling thirsty
- frequent urination
- bone pain
- kidney stones
- irregular heartbeat
- coma

If you think you, or a person you are caring for, have taken too much Calcium Chloride Injection BP, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

### What are possible side effects from using Calcium Chloride Injection BP?

These are not all the possible side effects you may have when taking Calcium Chloride Injection BP. If you experience any side effects not listed here, tell your healthcare professional.

- calcium taste in the mouth
- hot flushes
- burning sensation at the site of injection
- temporary low blood pressure
- tingling or pricking (“pins and needles”) sensation

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

#### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

#### Storage:

Calcium Chloride Injection BP is stored by a healthcare professional, between 15°C and 30°C. Protect from freezing. Avoid excessive heat. Keep out of reach and sight of children.

#### If you want more information about Calcium Chloride Injection BP:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer’s website [www.sterimaxinc.com](http://www.sterimaxinc.com), or by calling 1-800-881-3550.

This leaflet was prepared by:

SteriMax Inc.  
Oakville, Ontario  
L6H 6R4

Last Revised: SEP 18, 2024